welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!
enrolling by invitation

Phase III Study With Idebenone in Patients With Duchenne Muscular Dystrophy (SIDEROS-E)

key information

study id #: NCT03603288

condition: Duchenne Muscular Dystrophy

status: enrolling by invitation

purpose:

The purpose of the study is to assess the long-term safety and efficacy of idebenone in patients with Duchenne muscular dystrophy (DMD) who completed the SIDEROS study.

intervention: idebenone 150 mg film-coated tablets

mechanism of action: Antioxidant to support respiratory health

results: https://clinicaltrials.gov/ct2/show/results/NCT03603288

last updated: February 25, 2020